Vanguard Capital Management’s Insight Molecular Diagnostics IMDX Stock Holding History
Bought
Maintained
Sold
Other funds holding IMDX
AIC
Vanguard Capital Management's IMDX Position: Q3 2026 in Review
Vanguard Capital Management reduced its Insight Molecular Diagnostics (IMDX) stake by 0.61% in Q3 2026, selling an estimated $19.7K and leaving 731,391 shares worth $2.63M. The position accounts for ﹤0.01% of the portfolio, ranked #3287.
Vanguard Capital Management first reported a position in IMDX in Q1 2026 and has held it in 3 quarters since. The position peaked at $4.34M in Q2 2026. 40 funds tracked by Wall St. Rank hold IMDX as of Q3 2026.
- Vanguard Capital Management held 731,391 shares of Insight Molecular Diagnostics worth $2.63M as of Q3 2026.
- Vanguard Capital Management sold 4,456 Insight Molecular Diagnostics shares in Q3 2026, an estimated $19.7K.
- Insight Molecular Diagnostics made up ﹤0.01% of Vanguard Capital Management's portfolio in Q3 2026, its #3287 holding.
- Vanguard Capital Management first reported a position in Insight Molecular Diagnostics in Q1 2026 and has held it in 3 quarters since.
- Vanguard Capital Management's Insight Molecular Diagnostics position peaked at $4.34M in Q2 2026.
- 40 funds tracked by Wall St. Rank held Insight Molecular Diagnostics as of Q3 2026.
Based on Vanguard Capital Management's 13F filing for Q3 2026, filed 13 Nov 2026.